NeuroPace (NPCE) Long-Term Debt Repayments (2020 - 2025)
NeuroPace's quarterly Long-Term Debt Repayments came in at $61.9 million in Q2 2025, up 6190100.0% quarter-over-quarter from -$1000.0 in Q4 2020.
NeuroPace has reported Long-Term Debt Repayments for 2 years, with the latest figure at $61.9 million in Q2 2025.
- For the quarter ending Q2 2025, Long-Term Debt Repayments changed N/A year-over-year to $61.9 million; the trailing twelve-month figure through Dec 2025 stood at $61.9 million (changed N/A YoY), and the FY2025 full-year result was $60.5 million, changed N/A from the prior year.
- Long-Term Debt Repayments for Q2 2025 stood at $61.9 million, up from -$1000.0 in the prior quarter.
- The five-year high for Long-Term Debt Repayments was $61.9 million in Q2 2025, with the low at $61.9 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 1.42 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 1.00 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | - |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | - |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | - |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | - |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | - |
| 10 | NeuroPace | 558.86 Mn | 504.88 Mn | 18.05 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 61.90 Mn |
| Jun 30, 2025 | 61.90 Mn |
| Dec 31, 2020 | -1,000.00 |
| Dec 31, 2020 | -1,000.00 |
| Sep 30, 2020 | 47.60 Mn |
| Sep 30, 2020 | 47.60 Mn |